Yosuke Kawashima

Dr. Yosuke Kawashima


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
YTYuri Taniguchi
Yuri Taniguchi
TSTsuneo Shimokawa
Tsuneo Shimokawa
YTYuichi Takiguchi
Yuichi Takiguchi
TMToshihiro Misumi
Toshihiro Misumi
YNYukiko Nakamura
Yukiko Nakamura
HOHiroaki Okamoto
Hiroaki Okamoto
Purpose: The addition of cytotoxic chemotherapy to immune-checkpoint inhibitor (ICI) may enhance antitumor effects. We conducted an open-label randomized phase II/III study to evaluate nivolumab + docetaxel combination therapy in comparison with nivolumab monotherapy for previously treated ICI-naïve non–small cell lung cancer (NSCLC). Patients and Methods: The primary endpoint of the phase III study was overall survival (OS), and the secondary endpoints included progression-free survival (PFS), overall response rate (ORR), and toxicity. As ICI and platinum-doublet combination chemotherapy was approved in the first-line setting during this study, patient accrual was discontinued. Results: One hundred twenty-eight patients (each arm, n = 64) were included in the full analysis set. The median OS in nivolumab (arm A) and nivolumab + docetaxel (arm B) was 14.7 months (95% CI, 11.4–18.7) and 23.1 months (95% CI, 16.7–NR), respectively. The HR for OS was 0.63 (90% CI, 0.42–0.95; P = 0.0310). The median PFS in arms A and arm B was 3.1 months (95% CI, 2.0–3.9) and 6.7 months (95% CI, 3.8–9.4), respectively. The HR for progression was 0.58 (95% CI, 0.39–0.88; P = 0.0095). The ORR was 14.0% (95% CI, 6.3–25.8) in arm A and 41.8% (95% CI, 28.7–55.9) in arm B. Hematotoxicity and gastrointestinal adverse events were more common in arm B than in arm A. Two treatment-related deaths were observed, including one patient in arm A who died of pneumonitis and one in arm B who died of myocarditis. Conclusions: Despite a slightly elevated toxicity, the addition of docetaxel to nivolumab has significantly prolonged the OS and PFS of patients with previously treated ICI-naïve NSCLC.

29 April 2025 in Clinical Cancer Research
Verified
Journal Article
Open access
SKShintaro Kanda
Shintaro Kanda
SNSeiji Niho
Seiji Niho
TKTakayasu Kurata
Takayasu Kurata
SNShogo Nomura
Shogo Nomura
YKYosuke Kawashima
Yosuke Kawashima
YOYuichiro Ohe
Yuichiro Ohe
Purpose: This study was performed to confirm the superiority in overall survival (OS) of EGFR tyrosine kinase inhibitor (TKI gefitinib or osimertinib) monotherapy versus EGFR TKI with intercalation of cisplatin plus pemetrexed as the first-line treatment for patients with advanced non-squamous non–small cell lung cancer (NSqNSCLC) harboring EGFR mutation. Patients and Methods: This was an open-label, multicenter, randomized phase III study. Patients with chemotherapy-naïve advanced or recurrent NSqNSCLC harboring EGFR mutation (exon 19 deletion or exon 21 L858R point mutation) were randomly assigned (1:1) to EGFR-TKI monotherapy or the EGFR TKI plus intercalated chemotherapy group. The primary endpoint was OS, and the secondary endpoints included progression-free survival (PFS). Results: From December 2015 to October 2020, 501 patients were randomized. The EGFR TKI was changed from gefitinib to osimertinib in October 2018 (gefitinib cohort: n = 308 and osimertinib cohort: n = 193). There was no survival advantage in the EGFR TKI plus intercalated chemotherapy group; the median survival time of both groups was 48.0 months (HR, 0.985; 91.4% confidence interval, 0.796–1.219; one-sided P = 0.4496). The median PFS time was 12.0 months in the EGFR-TKI monotherapy group and 18.0 months in the EGFR TKI plus intercalated chemotherapy group (HR, 0.762; 95% confidence interval, 0.628–0.925; one-sided P = 0.003). The OS and PFS trends in both gefitinib and osimertinib cohorts were identical to those in the entire population. Conclusions: The intercalation of cisplatin plus pemetrexed after the response to EGFR TKI improved PFS but not OS compared with EGFR TKI monotherapy as the first-line treatment for patients with advanced NSqNSCLC harboring EGFR mutation.

13 November 2020 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYosuke Kawashima
Yosuke Kawashima
THToshiyuki Harada
Toshiyuki Harada
YFYuka Fujita
Yuka Fujita
TNTaku Nakagawa
Taku Nakagawa
KWKana Watanabe
Kana Watanabe
SSShunichi Sugawara
Shunichi Sugawara

25 July 2024 in Cancer Reports
Verified
Journal Article
Open access
SMSoichiro Minami
Soichiro Minami
YKYosuke Kawashima
Yosuke Kawashima
YMYasuhiko Munakata
Yasuhiko Munakata
MMMasahiro Matsuno
Masahiro Matsuno
SHShuichiro Hara
Shuichiro Hara
SSShunichi Sugawara
Shunichi Sugawara
Background: The expansion of preoperative immunochemotherapy has led to an increase in the number of patients with lung cancer receiving immune checkpoint inhibitors (ICIs). Therefore, oncologists should manage a variety of immune‐related adverse events (irAEs). One of the rare, life‐threatening, and recently proposed irAEs is cytokine release syndrome (CRS). Although the standard treatment of irAE is systemic administration of steroids, it has been suggested that tocilizumab may be an effective treatment option for CRS.Case: This case describes a 69‐year‐old man with stage IIIA lung adenocarcinoma who received chemotherapy and nivolumab, which is an ICI, as neoadjuvant immunochemotherapy. After the first administration, the patient developed severe skin rash, fever, and arthralgia. We suspected irAEs and administered systemic steroids. However, fever and arthralgia did not improve, although the skin rash disappeared. These were also significant challenges for surgery. Noting the elevated levels of inflammatory cytokines, we consulted a rheumatologist. Finally, we decided to terminate neoadjuvant therapy after one cycle and administer tocilizumab. Tocilizumab dramatically improved the patient's symptoms and allowed him to undergo radical surgery. Pathological findings revealed that the patient achieved a major pathological response.Conclusion: This indicates the potential effectiveness of early tocilizumab administration for ICI‐induced CRS, even in mild cases.

11 January 2024 in Cancer Reports
Verified
Journal Article
Open access
YMYosuke Murakami
Yosuke Murakami
YKYosuke Kawashima
Yosuke Kawashima
SCShinji Chiba
Shinji Chiba
SHShuichiro Hara
Shuichiro Hara
YYYusuke Yamazaki
Yusuke Yamazaki
SSShunichi Sugawara
Shunichi Sugawara
Background: Anaplastic lymphoma kinase (ALK)‐positive lung cancer has a better long‐term prognosis with ALK‐inhibitor than other lung cancers. However, resistance to ALK‐inhibitors and the control of metastases in the central nervous system (CNS) remain to be a challenge in the management of ALK‐positive lung cancer.Case: We present the case of a 23‐year‐old man who developed multiple brain metastases while receiving alectinib treatment for ALK‐positive lung cancer. After 3 months of lorlatinib initiation, brain metastases disappeared, and complete response (CR) was maintained.Conclusion: While lorlatinib can be used as first line therapy, this drug may be considered as second line or later option for patients with multiple brain metastases if the patient has already been treated with other ALK‐inhibitors since lorlatinib is thought to have good CNS penetration. This treatment option should be verified by further research.

1 November 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
HHHidetoshi Hayashi
Hidetoshi Hayashi
MNMakoto Nishio
Makoto Nishio
ATAkihiro Takaji
Akihiro Takaji
YGYasushi Goto
Yasushi Goto
SMSatoru Miura
Satoru Miura
TMTetsuya Mitsudomi
Tetsuya Mitsudomi
Purpose: Real-world, large-scale studies on the association between immune-related adverse events (irAE) and immune checkpoint inhibitor therapy effectiveness are limited. We evaluated overall survival (OS) and progression-free survival based on the occurrence and grade of irAEs. Patients and Methods: We used data from Japanese patients with unresectable advanced or recurrent non–small cell lung cancer (NSCLC) who received atezolizumab and were enrolled in J-TAIL, a multicenter, prospective, single-arm observational study. Results: Among the 1,002 patients, 190 (19.0%) developed irAEs. The most common irAEs were skin disorders (3.8%) of any grade and interstitial lung disease (1.5%) of grade ≥3. Patients who developed irAEs within 4 or 6 weeks of treatment initiation had higher baseline C-reactive protein levels than those without irAEs. OS was longer in patients with irAEs [HR, 0.66; 95% confidence interval (CI), 0.54–0.82], particularly in those with low-grade irAEs (HR, 0.45; 95% CI, 0.33–0.62), than in patients without irAEs. The HR (95% CI) for OS in patients with low-grade and high-grade skin or endocrine disorder–related irAEs was 0.42 (0.28–0.64) and 0.37 (0.15–0.88), respectively. The HR (95% CI) for OS in patients with low-grade and high-grade irAEs other than skin or endocrine disorders was 0.44 (0.30–0.65) and 1.27 (0.96–1.69), respectively. Conclusions: In patients with unresectable advanced or recurrent NSCLC treated with atezolizumab in real-world settings, irAEs are associated with a clinical benefit except in those with high-grade irAEs other than skin and endocrine disorders. Significance: Immune checkpoint inhibitors are useful for treating NSCLC but can cause life-threatening irAEs. This study had a large sample size and stratified the analysis by irAE type and grade. The results suggest that improved management of irAEs may improve the therapeutic effect of atezolizumab.